Health Canada has authorized use of tisagenlecleucel (Kymriah™), making it the first chimeric antigen receptor (CAR) T-cell therapy to receive...
Tisagenlecleucel (Kymriah) will be available for certain leukemia patients through the Cancer Drugs Fund.
Escalating methotrexate (MTX) may produce better outcomes than high-dose MTX in children and young adults with T-cell acute lymphoblastic leukemia...
The National Health Service (NHS) of England has announced that tisagenlecleucel (Kymriah®), a chimeric antigen receptor (CAR) T-cell therapy,...
From the Journals
The findings are based on the Children’s Oncology Group (COG) AALL0434 trial.
The drug was approved in Europe for adults in 2015.
The European Commission (EC) has expanded the approved indication for blinatumomab (Blincyto®), a bispecific, CD19-directed, CD3 T-cell engager...
Tisagenlecleucel and axicabtagene ciloleucel can now be marketed throughout Europe.
The European Commission (EC) has granted approval for tisagenlecleucel (Kymriah®), a chimeric antigen receptor (CAR) T-cell therapy targeting CD19...
A drug typically used to treat acne shows promise for treating different types of leukemia.
Socioeconomic status (SES) may explain some racial/ethnic disparities in childhood cancer survival, according to new research. The study showed...